Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib as adjuvant therapy after radical resection for hepatocellular carcinoma
ChiCTR2200064030Phase 4Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of donafenib in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Recurrence-free survival. Started Sep 2022; status: recruiting.
02
Drugs
donafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2200064030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064030.